ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2024

    Author microcapwatchPosted on Categories HealthTags , , ,

    Zinzino group revenue increased 24% in Q2, compared with the previous year

    GOTHENBURG, Sweden, July 3, 2024 /PRNewswire/ — The revenue in June for Zinzino’s sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma’s external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3 (139.9) million compared with the previous year.

    Revenue in Zinzino’s sales markets increased by 24% in the second quarter of 2024 compared with the same period last year and amounted to SEK 481.9 (387.3) million. Total revenues in the Group increased by 24% in the second quarter and amounted to SEK 505.4 (407.9) million.

    Accumulated revenue for January – June 2024 increased by 20% to SEK 959.9 (801.6) million.

    Revenues were distributed as follows:

    Regions, mSEK

    24-jun

    23-jun

    Change

    Q2 2024

    Q2 2023

    Change

    YTD 2024

    YTD 2023

    Change

    The Nordics

    22.5

    23.7

    -5 %

    73.1

    71.2

    3 %

    141.2

    144.8

    -2 %

    Central Europe

    41.8

    36.9

    13 %

    136.7

    100.3

    36 %

    256.2

    191.2

    34 %

    East Europe

    32.0

    29.8

    7 %

    97.8

    94.4

    4 %

    191.6

    187.0

    2 %

    South & West Europe

    27.4

    21.9

    25 %

    88.0

    62.5

    41 %

    158.6

    111.5

    42 %

    The Baltics

    6.8

    7.0

    -3 %

    23.9

    21.6

    11 %

    47.7

    42.7

    12 %

    North America

    14.4

    6.6

    118 %

    46.1

    19.5

    136 %

    81.5

    39.1

    108 %

    Asia-Pacific

    2.5

    4.5

    -44 %

    12.7

    14.4

    -12 %

    25.1

    30.0

    -16 %

    Africa

    1.1

    1,0

    10 %

    3.6

    3.4

    6 %

    6.9

    7.1

    -3 %

    Zinzino

    148.5

    131.4

    13 %

    481.9

    387.3

    24 %

    908.8

    753.4

    21 %

    Faun Pharma

    5.8

    8.5

    -32 %

    23.5

    20.6

    14 %

    51.1

    48.2

    6 %

    Zinzino Group

    154.3

    139.9

    10 %

    505.4

    407.9

    24 %

    959.9

    801.6

    20 %

    Countries in regions:

    -The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden

    –Central Europe: Austria, Germany, Switzerland

    –East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania

    -South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Serbia, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey

    -The Baltics: Estonia, Latvia, Lithuania

    –North America: Canada, USA, Mexico

    –Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

    –Africa: South Africa

    For more information:

    Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

    Pictures for publication free of charge: [email protected]

    Certified Adviser: Carnegie Investment Bank AB (publ)

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/zinzino/r/zinzino-ab–publ–preliminary-sales-report-q2-2024,c4010624

    The following files are available for download:

    Cision View original content:https://www.prnewswire.co.uk/news-releases/zinzino-ab-publ-preliminary-sales-report-q2-2024-302188796.html

    Featured image: © SergeyNivens

    Disclaimer